{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-029342","form_type":"8-K","ticker":"KALV","cik":"0001348911","company_name":"KalVista Pharmaceuticals, Inc.","filed_at":"2024-03-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.891190+00:00","generated_at":"2026-06-04T23:42:51.109952+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"KalVista reports Phase 3 KONFIDENT success for sebetralstat, CEO transition, $150M financing","bullets":["Phase 3 KONFIDENT met all primary and key secondary endpoints; sebetralstat safety profile similar to placebo.","CEO transition: Benjamin Palleiko appointed CEO, succeeding prior CEO as part of commercial preparation.","Closed underwritten offering netting ~$150.1M from 7.0M shares and 3.5M pre-funded warrants at $15.25/share.","Net loss $29.0M ($0.84/sh) for fiscal Q3 ended Jan 31, 2024, vs $21.3M ($0.75) YoY; cash $75.6M.","NDA submission on track for H1 2024; UK MHRA granted Innovation Passport for sebetralstat."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-029342","json":"https://secwatch.observer/filing/0000950170-24-029342.json","markdown":"https://secwatch.observer/filing/0000950170-24-029342.md","text":"https://secwatch.observer/filing/0000950170-24-029342.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1348911/000095017024029342/0000950170-24-029342-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1348911/000095017024029342/kalv-20240311.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T23:42:51.109952+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2a67a4fad26c2387d4e7aad82bf4759be074108c","claim":"KalVista Pharmaceuticals, Inc. reported the fiscal quarter ended January 31, 2024 results: net income $29.0 million, EPS $(0.84) per weighted average basic and diluted share.","evidence_excerpt":"Net loss was $29.0 million, or $(0.84) per weighted average basic and diluted share, for the three months ended January 31, 2024","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1348911/000095017024029342/0000950170-24-029342-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fiscal quarter ended January 31, 2024"},{"label":"Net income","value":"$29.0 million"},{"label":"EPS","value":"$(0.84) per weighted average basic and diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}